Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03073733 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of Intravitreal Injection of Human Retinal Progenitor Cells in Adults With Retinitis Pigmentosa
A Phase 2 study, sponsored by jCyte.
- Completed
- Registry status
- Phase 2
- Development phase
- 84
- Enrollment target
NCT03073733 is a Phase 2 study that has completed, run by jCyte. The registered enrollment target is 84 participants.
The verdict
NCT03073733, a Phase 2 study, has completed, sponsored by jCyte.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 84 participants
- Enrollment target
Study Summary
This study evaluates the changes in visual function at 12 months following a single injection of human retinal progenitor cells compared to sham treated controls in a cohort of adult subjects with RP.
Interventions
- BIOLOGICAL human retinal progenitor cells
- OTHER Mock injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2017-03-01 |
| Est. Completion | 2020-11-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03073733
The ClinicalTrials.gov registry entry for NCT03073733 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 84 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is jCyte, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which human retinal progenitor cells is the first listed.
NCT03073733 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03073733 about?
NCT03073733 is a clinical study titled "Safety and Efficacy of Intravitreal Injection of Human Retinal Progenitor Cells in Adults With Retinitis Pigmentosa". This study evaluates the changes in visual function at 12 months following a single injection of human retinal progenitor cells compared to sham treated controls in a cohort of adult subjects with RP.
What is the current status of trial NCT03073733?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 84 participants. The study started on 2017-03-01. Estimated completion is 2020-11-13.
What interventions are being tested in trial NCT03073733?
The interventions under investigation include: human retinal progenitor cells (BIOLOGICAL), Mock injection (OTHER).
Who is sponsoring clinical trial NCT03073733?
This trial is sponsored by jCyte, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.